

Chemistry provides a new supply of a promising cancer and HIV treatment

Research (/Research) 📅 13 October 2017

A drug isolated from a marine pest holds promise for treating some of the world's nastiest diseases, and researchers would love to find out just how effective it is - if only they could get their hands on more. As it stands, the world's supply of the chemical is down to about half of what it was in the 1990s, and it is hard to extract in sufficient quantities from the feathery sea creatures that produce it.

Now, Stanford researchers have found a simpler and more efficient way to make this increasingly in-demand compound in the lab, they report October 6 in the journal Science. Their new synthetic supply will be enough to continue ongoing trials testing its effectiveness as a cancer immunotherapy and for treating Alzheimer's disease and HIV, for which any further supply was until now uncertain.

Principal investigator Paul Wender, a professor of chemistry and member of Stanford ChEM-H, said he got so excited about the project at one point, "I put on my lab coat and did some crystallizations," one of the basic steps of chemistry lab work usually left to students, not full professors. For him, the new paper is the result of decades of work and a happy accident in the Gulf of Mexico almost 50 years ago.

From three elephants to a salt shaker

Like many other naturally occurring chemicals put into service as pharmaceuticals, bryostatin was discovered following what was essentially a fishing expedition. In the 1960s, having had some success developing drugs from terrestrial flora and fauna, scientists began to shift attention to marine life.

The story of bryostatin itself began in 1968, when a marine biologist working in the Gulf of Mexico collected a plethora of marine organisms and sent them to the National Cancer Institute for analysis. One of those organisms, *Bugula neritina*, a pest best known for fouling up marine environments, showed some promise as an anti-cancer agent. A decade and a half later, researchers reported the structure of the active ingredient, which they dubbed bryostatin 1 after the animal's common name, brown bryozoan.

Unfortunately, bryostatin 1 is very hard to come by. When NCI scientists went back and swept up 14 tons of *B. neritina*, they managed to extract just 18 grams of bryostatin.

"It's basically three elephants going down to a salt shaker," Wender said.

Pharmaceutical Companies

[[A \(/directory/a\)](#) | [B \(/directory/b\)](#) | [C \(/directory/c\)](#) | [D \(/directory/d\)](#) | [E \(/directory/e\)](#) | [F \(/directory/f\)](#) | [G \(/directory/g\)](#) | [H \(/directory/h\)](#) | [I \(/directory/i\)](#) | [J \(/directory/j\)](#) | [K \(/directory/k\)](#) | [L \(/directory/l\)](#) | [M \(/directory/m\)](#) | [N \(/directory/n\)](#) | [O \(/directory/o\)](#) | [P \(/directory/p\)](#) | [Q \(/directory/q\)](#) | [R \(/directory/r\)](#) | [S \(/directory/s\)](#) | [T \(/directory/t\)](#) | [U \(/directory/u\)](#) | [V \(/directory/v\)](#) | [W \(/directory/w\)](#) | [X \(/directory/x\)](#) | [Z \(/directory/z\)](#)]

Worse, subsequent studies showed that *B. neritina* produces bryostatin only in depths greater than about 10 feet and in warmer seas closer to the equator, and only during certain times of the year. (In fact, the NCI's 14-ton collection came from California, because subsequent samples from the Gulf of Mexico proved inactive.) And while there was a way to synthesize bryostatin in the lab, it took 57 steps and was not very efficient.

Improving on nature

Wender and his group have been working with bryostatin analogs - chemicals inspired by bryostatin, but not quite the same - since the 1980s but only recently began thinking about how to make bryostatin itself in a lab.

"Ordinarily, we're in the business of making chemicals that are better than the natural products" such as bryostatin, Wender said. Wender and his lab's job, in other words, is to come up with chemicals inspired by nature, but more effective.

"But when we started to realize that clinical trials a lot of people were thinking about were not being done because they didn't have enough material, we decided, 'That's it, we're going to roll up our sleeves and make bryostatin because it is now in demand,'" Wender said.

Dusting off the lab coat

After decades of experience with bryostatin analogs and two years of concerted effort, the lab came up with a much shorter, 29-step process and a yield of 4.8 percent, tens of thousands of times more efficient than extracting bryostatin from *B. neritina*, and substantially simpler and more efficient than the previous synthetic approach.

"The talent and dedication of this group made possible an achievement which many had thought impossible," Wender said. "We are so fortunate to have people who are undeterred by that."

The team members have now produced over 2 grams of bryostatin 1, and once production is scaled up, Wender said, they expect manufacturers could produce about 20 grams per year, enough to cover clinical and research needs. That is a bit more than was ever extracted from *B. neritina* and enough to treat about 20,000 cancer patients or 40,000 Alzheimer's patients.

The results could also be a boon for HIV/AIDS research. In late September, the team reported that a bryostatin 1 analog could help wake latent HIV-infected cells, making them more susceptible to attack by HIV drugs or the immune system. With new insight into - and a new supply of - bryostatin 1, Wender said, "we have an opportunity to start in earnest a clinical conversation about eradicating HIV/AIDS."

Paul A Wender, Clayton T Hardman, Stephen Ho, Matthew S Jeffreys, Jana K Maclaren, Ryan V Quiroz, Steven M Ryckbosch, Akira J Shimizu, Jack L Sloane, Matthew C Stevens.

Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.

Science 13 Oct 2017, Vol. 358, Issue 6360, pp. 218-223. doi:

10.1126/science.aan7969 (<http://dx.doi.org/10.1126/science.aan7969>).



World Pharma News
19,762 likes

Like Page Share

Be the first of your friends to like this



Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, Shimizu A, Ryckbosch SM, Near KE, Chun TW, Wender PA, Zack JA. *In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.* *PLoS Pathog.* 2017 Sep 21;13(9):e1006575. doi: 10.1371/journal.ppat.1006575 (<http://dx.doi.org/10.1371/journal.ppat.1006575>).

◀ 1

Most Popular Now

FDA approves first biosimilar for the treatment of... (/fda/4104-fda-approves-first-biosimilar-for-the-treatment-of-cancer)

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

'Exciting' discovery on path to develop new type o... (/research/4106-exciting-discovery-on-path-to-develop-new-type-of-vaccine-to-treat-global-viruses)

Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect mil...

Bristol-Myers Squibb and Halozyme enter global col... (/bms/4105-bristol-myers-squibb-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhance-technology)

Bristol-Myers Squibb Company (NYSE:BMJ) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced a global collaboration and license agreement to develop subcutaneous...

Type 2 diabetes is a reversible condition (/development/4103-type-2-diabetes-is-a-reversible-condition)

A body of research putting people with Type 2 diabetes on a low calorie diet has confirmed the underlying causes of the condition and established that it is reversible. P...

Business & Industry

- Pfizer reviewing strategic alternatives for Consumer Healthcare business ([/pfizer/4145-pfizer-reviewing-strategic-alternatives-for-consumer-healthcare-business](#))
- Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer ([/astrazeneca/4142-tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-the-1st-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer](#))
- Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams ([/roche/4138-roche-launches-navify-tumor-board-solution-to-provide-decision-support-to-oncology-care-teams](#))
- Pfizer launches novel programs to put important support services at the fingertips of cancer patients ([/pfizer/4135-pfizer-launches-novel-programs-to-put-important-support-services-at-the-fingertips-of-cancer-patients](#))
- Caregivers wish liver cancer received greater public awareness in the U.S., new survey reveals ([/bms/4133-caregivers-wish-liver-cancer-received-greater-public-awareness-in-the-u-s-new-survey-reveals](#))

Research & Development

- Chemistry provides a new supply of a promising cancer and HIV treatment ([/research/4146-chemistry-provides-a-new-supply-of-a-promising-cancer-and-hiv-treatment](#))
- New drug hope for rare bone cancer patients ([/research/4144-new-drug-hope-for-rare-bone-cancer-patients](#))
- Allergy drug improves function in patients with chronic injury from multiple sclerosis ([/research/4143-allergy-drug-improves-function-in-patients-with-chronic-injury-from-multiple-sclerosis](#))
- Indian government needs to do more to tackle rising sale of unapproved antibiotics ([/research/4141-indian-government-needs-to-do-more-to-tackle-rising-sale-of-unapproved-antibiotics](#))
- Safe to treat dementia patients with clot-busting drugs ([/research/4140-safe-to-treat-dementia-patients-with-clot-busting-drugs](#))
- A need for bananas? Dietary potassium regulates calcification of arteries ([/research/4134-a-need-for-bananas-dietary-potassium-regulates-calcification-of-arteries](#))
- The Nobel Prize in Chemistry 2017 - Cool microscope technology revolutionises biochemistry ([/development/4132-the-nobel-prize-in-chemistry-2017-cool-microscope-technology-revolutionises-biochemistry](#))

Conferences & Events

- Social Media in the Pharmaceutical Industry ([/events/4139-social-media-in-the-pharmaceutical-industry](#))
- SMI presents Europe's leading 10th annual conference and exhibition: Pre-Filled Syringes Europe 2018 ([/events/4113-smi-presents-europe-s-leading-10th-annual-conference-and-exhibition-pre-filled-syringes-europe-2018](#))
- Ophthalmic Drugs Conference 2017 ([/events/4097-ophthalmic-drugs-conference-2017](#))
- Lyophilization USA Conference 2017 ([/events/4086-lyophilization-usa-conference-2017](#))
- IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies ([/events/3955-it-transformation-and-cloud-content-management-for-medtech-biotechnology-and-pharmaceutical-companies](#))
- The future has arrived #CUBETechFair ([/events/3925-the-future-has-arrived-cubetechfair](#))
- eyeforpharma Philadelphia 2017: Be the trusted healthcare partner #efpPhilly ([/events/3858-eyeforpharma-philadelphia-2017-be-the-trusted-healthcare-partner](#))

Regulatory Affairs

- FDA awards 15 grants for clinical trials to stimulate product development for rare diseases ([/fda/4137-fda-awards-15-grants-for-clinical-trials-to-stimulate-product-development-for-rare-diseases](#))
- FDA awards six grants for natural history studies in rare diseases ([/fda/4136-fda-awards-six-grants-for-natural-history-studies-in-rare-diseases](#))
- FDA improves access to reports of adverse drug reactions ([/fda/4126-fda-improves-access-to-reports-of-adverse-drug-reactions](#))
- FDA conducts major global operation to protect consumers from potentially dangerous prescription drugs sold online ([/fda/4121-fda-conducts-major-global-operation-to-protect-consumers-from-potentially-dangerous-prescription-drugs-sold-online](#))
- FDA approves first biosimilar for the treatment of cancer ([/fda/4104-fda-approves-first-biosimilar-for-the-treatment-of-cancer](#))
- FDA approves Mylotarg for treatment of acute myeloid leukemia ([/fda/4087-fda-approves-mylotarg-for-treatment-of-acute-myeloid-leukemia](#))
- FDA approval brings first gene therapy to the United States ([/fda/4082-fda-approval-brings-first-gene-therapy-to-the-united-states](#))

You are here: [Home \(/\)](#) / [Research \(/research\)](#) / Chemistry provides a new supply of a promising cancer and HIV treatment

About

- [Home \(/\)](#)
- [Advertise \(/advertise\)](#)
- [Privacy \(/terms-and-conditions\)](#)
- [Terms of Use \(/terms-and-conditions#section1\)](#)
- [Contact \(/contact\)](#)

[Submit Your News! \(/advertise#submit\)](#)

Latest WORLD PHARMA JOBS

- Senior Director, Global Economics
(<http://www.worldpharmajobs.com/jobs/senior-director-global-economics/>)
- Principal Health Informatics Scientist
(<http://www.worldpharmajobs.com/jobs/principal-health-informatics-scientist/>)
- Digital Acceleration Director
(<http://www.worldpharmajobs.com/jobs/digital-acceleration-director/>)
- Head of Business Management
(<http://www.worldpharmajobs.com/jobs/head-of-business-management/>)
- Associate Director, Strategy & Operations
(<http://www.worldpharmajobs.com/jobs/associate-director-strategy-operations/>)
- Director Medical Communications
(<http://www.worldpharmajobs.com/jobs/director-medical-communications/>)

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:

- Facebook
(<http://www.facebook.com/worldpharmanews>)
- Twitter
(<http://twitter.com/worldpharmanews>)
- Google+
(<https://www.google.com/+Worldpharmanews>)
- LinkedIn
(<https://www.linkedin.com/groups/40567>)
- XING
(<https://www.xing.com/communities/groups/world-pharma-news-d946-1067200>)
- RSS
(<http://feedproxy.google.com/worldpharmanews>)

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

[Subscribe](#)

Global Medical Lead Digestive
Health Consumer Healthcare
(<http://www.worldpharmajobs.com/jobs/global-medical-lead-digestive-health-consumer-healthcare/>)

© World Pharma News (<http://www.worldpharmanews.com>) 2006 - 2017. All Rights Reserved.

Our top projects: World Pharma News (<http://www.worldpharmanews.com>) | WORLD PHARMA JOBS (<http://www.worldpharmajobs.com>) | PharmaNews.eu (<http://www.pharmanews.eu>) | eHealthNews.eu (<http://www.ehealthnews.eu>) | (HEALTH IT) SPACE (<http://www.healthitspace.eu>)